An investigational quadrivalent Neisseria meningitidis serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine (MenACWY-TT) has been developed to expand available options for vaccination against invasive meningococcal disease.
A total of 784 healthy adolescents and young adults 11 to 25 years of age were randomized (3:1) to receive a single dose of the MenACWY-TT vaccine or a licensed MenACWY diphtheria toxoid conjugate vaccine (MenACWY-DT). An additional nonrandomized group of 88 subjects 10 years of age received the MenACWY-TT vaccine only (MenACWY-TT/10). Immunogenicity was assessed 1 month postvaccination by human complement serum bactericidal assay (hSBA) for all serogroups. Solicited local and general symptoms were recorded for 8 days postvaccination and safety outcomes for 6 months.
One month postvaccination, 81.9% to 96.1% of subjects had hSBA titers ≥1:8 in the MenACWY-TT group compared with 70.7% to 98.8% in the MenACWY-DT group. Exploratory analyses showed the proportion of subjects with hSBA titers ≥1:4 and ≥1:8 to be higher in the MenACWY-TT group than in the MenACWY-DT group for serogroups A, W-135, and Y. GMTs adjusted for age strata and baseline titer 1 month postvaccination were higher in the MenACWY-TT group than in the MenACWY-DT group for all 4 serogroups. The percentage of subjects reporting solicited local and general symptoms of any or Grade 3 severity or serious adverse events was similar between the 2 groups. Immune response and reactogenicity in the MenACWY-TT/10 group was similar to that in the MenACWY-TT group, except for higher hSBA-MenA GMTs in the MenACWY-TT/10 group.
The investigational MenACWY-TT vaccine was immunogenic in adolescents and young adults, with an acceptable safety profile.
From the *Kaiser Permanente Vaccine Study Center, Oakland, CA; †GlaxoSmithKline Biologicals, King of Prussia, PA; and ‡GlaxoSmithKline Biologicals, Wavre, Belgium.
Accepted for publication November 3, 2010.
Supported by GlaxoSmithKline Biologicals (109377/NCT00454909). GlaxoSmithKline was involved in all stages of the study conduct and analysis (ClinicalTrials.gov Identifier: 00454909). GlaxoSmithKline Biologicals also took in charge all costs associated with the development and publishing of the present manuscript. All authors had full access to the data. The corresponding author had final responsibility to submit for publication. The principal investigator for this study supported by GlaxoSmithKline Biologicals and has received grants from Novartis and Sanofi-Pasteur (to R.B.).
Authors Y.B., V.B., L.F., and J.M. are employees of GlaxoSmithKline Biologicals; Y.B., L.R.F., and J.M.M. report ownership of stock options.
Address for correspondence to: Roger Baxter, MD, 1 Kaiser Plaza, Ordway Building, Oakland, CA 94612. E-mail: email@example.com.